ASCO 2026

ASCO 2026
May 29-June 02, 2026
Chicago, IL

American Society of Clinical Oncology 2026.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (7)

    A Phase 3 Study of Sacituzumab Govitecan in Patients with Previously Treated Extensive-Stage Small-Cell Lung Cancer

    • Author(s): Dowlati, A
    • trodelvy
    • Oncology

    Subgroup analysis of participants (pts) with HER2 IHC0 in the ASCENT-07 study of sacituzumab govitecan (SG) vs chemotherapy in HR+/ HER2− metastatic breast cancer (mBC)

    • Author(s): Park, Y
    • trodelvy
    • Oncology

    ASCENT-04: analysis of efficacy by biomarker subgroups with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC)

    • Author(s): Tolaney, S
    • trodelvy
    • Oncology

    Progression-free survival after next line of treatment and subsequent therapies (subs tx) in the ASCENT-03 study of participants (pts) with previously untreated metastatic triple-negative breast cancer treated with sacituzumab govitecan vs chemotherapy

    • Author(s): Hurvitz, S
    • trodelvy
    • Oncology

    Progression-free survival after next line of treatment and subsequent therapies in the ASCENT-04 study of ptswith previously untreated PD-L1+ metastatic (tnbc) treated with sacituzumab govitecan + pembrolizumab vs chemotherapy + pembro

    • Author(s): Kalinsky, K
    • trodelvy
    • Oncology

    ASCENT-03: Efficacy by biomarker subgroup with sacituzumab govitecan (SG) vs chemotherapy (chemo) in participants (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitors (PD-[L]1i)

    • Author(s): Barrios, C
    • trodelvy
    • Oncology

    NAPISTAR 1-01: Results of phase 1 dose escalation of monotherapy with TUB-040, a novel NaPi2b-targeting exatecan ADC, in patients (pts) with platinum-resistant ovarian cancer (PROC)

    • Author(s): Van Gorp, T
    • tub-040
    • Oncology
    • Oral